"id:ID","uuid","description","studyInvestigationalInterventions","name","documentVersion","label","id","studyDesignRationale","studyEstimands","bcCategories"
"820","f4931f59-6fef-4edf-baca-36c7de585d7c","The main design for the study","[]","Study Design 1","","","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","[]","[]"
